Navigation Links
GSK Initiates Phase III Programme for Novel Type 2 Diabetes Medication, Syncria(R) (albiglutide)
Date:2/17/2009

LONDON, Feb. 17 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria(R) (albiglutide) in men and women with type 2 diabetes. The Phase III programme will include more than 4,000 patients.

"Despite continued advances in diabetes treatment, this devastating disease continues to increase at an alarming pace worldwide. It is clear that new therapies are needed to better control type 2 diabetes and to improve people's lives," said Carlo Russo, MD., Senior Vice President, Biopharm Development, GlaxoSmithKline. "Albiglutide is a novel biological currently being investigated to determine its potential to help people control their blood sugar, particularly when oral treatments alone may not provide an adequate response."

About the Phase III Programme

The Phase III programme for albiglutide will begin with five studies in early 2009. The objective of the programme is to demonstrate durable efficacy and cardiovascular safety of albiglutide as mono- and add-on therapy, in patients with type 2 diabetes. The primary efficacy endpoint for all studies will be the change from baseline in HbA1c compared to placebo and/or active comparators. A majority of the studies will include active comparators, including metformin, sulphonylurea, thiazolidinedione (TZD) insulin and a dipeptidyl peptidase four inhibitor (DPP IV). The study duration is expected to be two to three years and the main dose and regimen for the programme will be 30 mg weekly.

About Albiglutide and Type 2 Diabetes

Albiglutide is an investigational biological, injectable form of human GLP-1 -- a peptide that acts throughout the body to help maintain normal blood-sugar levels and to control appetite. Normally, GLP-1 levels rise during a
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
2. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
3. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
4. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
5. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
6. Harbinger Research Initiates Coverage on HearAtLast
7. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
8. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
9. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
10. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
11. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Oxford Gene Technology (OGT) is a ... include CytoSure heamatological cancer +SNP Array, CytoSure ISCA ... array, CytoSure ISCA sample tracking spike-ins and CytoSure ... as targeted sequencing services, SureSeq Solid Tumour Panel ... analysis, cytosure services and aCGH for CNV analysis. ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Roaming the ... preserved mummy became famous as the "Ice Man" no doubt ... of that may still not have shielded the Ice Man, ... A human,s genetic risk for atherosclerosis, or "hardening of the ... thousands of years ago, a new study finds. ...
(Date:8/1/2014)... LA The Health Resources and Services Administration ... Orleans School of Nursing an Advanced Nursing Education ... years. The funding will support training interprofessional teams ... for military veterans and diverse populations with behavioral ... DNP, CRNA, LSUHSC Nurse Anesthesia Program Director and ...
(Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... "Des" O,Neill, MA, MD, FRCPI, AGSF, FRCP(Glasg), FRCP, FRCP(Edin), ... the 2014 recipient of the Joseph T. Freeman Award. ... geriatrics and is awarded to a prominent physician in ... practice who is a member of the Society,s ...
(Date:8/1/2014)... 01, 2014 Lifeinsurancenomedicalexam.info has released ... insurance for clients who have high cholesterol levels. ... find and qualify for no medical exam life insurance. ... any background medical check-ups. , Since there are no ... level will qualify in just a few minutes. However, ...
Breaking Medicine News(10 mins):Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3Health News:'Ice Man' Mummy May Have Been at Risk of Heart Disease 2Health News:LSUHSC Nursing awarded $1 million grant to improve care for veterans 2Health News:O'Neill to receive GSA's 2014 Joseph T. Freeman Award 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2
... in French . A team of ... have discovered a type of "cellular bilingualism" a ... different methods of communication to exchange information. "Our work ... function of dopaminergic, serotonergic and cholinergic neurons in diseases ...
... By Alan Mozes HealthDay Reporter , THURSDAY, March ... therapy may have gotten a little closer to reality, with ... hearts that were dangerously swollen after heart attacks. The ... bone marrow, then injecting them into the patient,s damaged heart. ...
... , WEDNESDAY, March 16 (HealthDay News) -- ... children participating in their school,s band, a new study ... high school band and found they were heavily contaminated ... which are associated with minor to serious infections and ...
... for the first time that stem cells injected into ... improved function to injured heart areas, according to a ... the American Heart Association . , Researchers said that ... findings are promising for the more than five million ...
... increasing frequency, parents of children with autism spectrum disorder ... their children wander or unexpectedly run away. One mother ... wandered away from her home, despite efforts to lock ... this problem, Autism Speaks, the world,s largest autism science ...
... -- Many American children who qualify for public health ... parents are confused about enrollment and eligibility, new research ... low-income households in Oregon and found that about 23 ... were not enrolled in the Oregon Health Plan (OHP), ...
Cached Medicine News:Health News:'Bilingual' neurons may reveal the secrets of brain disease 2Health News:Stem Cell Therapy Shrinks Enlarged Hearts 2Health News:Stem Cell Therapy Shrinks Enlarged Hearts 3Health News:Heart damage improves, reverses after stem cell injections in a preliminary human trial 2Health News:Autism Speaks supports new diagnostic code for individuals with autism with history of wandering 2Health News:Parents Often Confused About Kids' Health Coverage 2
(Date:8/1/2014)... -- Aspire Technology Partners (Aspire) announced today that it has ... designation recognizes Aspire for delivering outstanding customer service to customers ... "Achieving exceptional results for our customers is core ... and CEO of Aspire. "We are pleased Cisco has recognized ... and are proud to be part of the Cisco channel." ...
(Date:8/1/2014)... , Aug. 1, 2014 ... of the "Global Medical Biosensors Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Medical biosensors ... help of physicochemical detectors. These biosensors monitor health ... invasive and non-invasive methods. They are cost-effective and ...
(Date:8/1/2014)... CHICAGO , Ill. and PALO ALTO, ... ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a ... the cystic fibrosis (CF) community through the CFChef Shares ... September 15, 2014, as part of AbbVie,s CFChef program ... – to encourage patients to maintain a healthy diet ...
Breaking Medicine Technology:Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3
... NEW YORK, June 13, 2011 Reportlinker.com ... is available in its catalogue: ... in Key SADC Countries ... aim of this research service is to ...
... 2011 Science, public health, and regulatory highlights from ... this document is designed for credentialed journalists. Release dates and ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... or enforcement actions due to legal limitations. ...
Cached Medicine Technology:Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 2Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 3
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
Size: Medium. 22.50 mm by 24.00 mm. Clear lucite. Supplied sterile....
... x 100 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Medicine Products: